Long-Term Outcomes of Cognitive-Behavioral Therapy for Adolescent Body Dysmorphic Disorder by Krebs, Georgina et al.
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
King’s Research Portal 
 
DOI:
10.1016/j.beth.2017.01.001
Document Version
Publisher's PDF, also known as Version of record
Link to publication record in King's Research Portal
Citation for published version (APA):
Krebs, G., de la Cruz, L. F., Monzani, B., Bowyer, L., Anson, M., Cadman, J., ... Mataix-Cols, D. (2017). Long-
Term Outcomes of Cognitive-Behavioral Therapy for Adolescent Body Dysmorphic Disorder. Behavior Therapy,
48(4), 462-473. DOI: 10.1016/j.beth.2017.01.001
Citing this paper
Please note that where the full-text provided on King's Research Portal is the Author Accepted Manuscript or Post-Print version this may
differ from the final Published version. If citing, it is advised that you check and use the publisher's definitive version for pagination,
volume/issue, and date of publication details. And where the final published version is provided on the Research Portal, if citing you are
again advised to check the publisher's website for any subsequent corrections.
General rights
Copyright and moral rights for the publications made accessible in the Research Portal are retained by the authors and/or other copyright
owners and it is a condition of accessing publications that users recognize and abide by the legal requirements associated with these rights.
•Users may download and print one copy of any publication from the Research Portal for the purpose of private study or research.
•You may not further distribute the material or use it for any profit-making activity or commercial gain
•You may freely distribute the URL identifying the publication in the Research Portal
Take down policy
If you believe that this document breaches copyright please contact librarypure@kcl.ac.uk providing details, and we will remove access to
the work immediately and investigate your claim.
Download date: 06. Nov. 2017
Long-Term Outcomes of Cognitive-Behavioral Therapy for
Adolescent Body Dysmorphic Disorder
Georgina Krebs
South London and Maudsley NHS Foundation Trust
Institute of Psychiatry, Psychology and Neuroscience, King’s College London
Lorena Fernández de la Cruz
Karolinska Institutet
Benedetta Monzani
Institute of Psychiatry, Psychology and Neuroscience, King’s College London
Laura Bowyer
South London and Maudsley NHS Foundation Trust
Martin Anson
South London and Maudsley NHS Foundation Trust
Canterbury Christ Church University
Jacinda Cadman
Griffith University
Isobel Heyman
Institute of Psychiatry, Psychology and Neuroscience, King’s College London
Great Ormond Street Hospital and Institute of Child Health, University College London
Cynthia Turner
University of Queensland
David Veale
South London and Maudsley NHS Foundation Trust
Institute of Psychiatry, Psychology and Neuroscience, King’s College London
David Mataix-Cols
Institute of Psychiatry, Psychology and Neuroscience, King's College London
Karolinska Institutet and Stockholm Health Care Services
Emerging evidence suggests that cognitive-behavioral ther-
apy (CBT) is an efficacious treatment for adolescent body
dysmorphic disorder (BDD) in the short term, but
longer-term outcomes remain unknown. The current study
aimed to follow up a group of adolescents who had
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originally participated in a randomized controlled trial of
CBT for BDD to determine whether treatment gains were
maintained. Twenty-six adolescents (mean age = 16.2, SD =
1.6) with a primary diagnosis of BDD received a course of
developmentally tailored CBT and were followed up over
12 months. Participants were assessed at baseline, midtreat-
ment, posttreatment, 2-, 6-, and 12-month follow-up. The
primary outcome measure was the clinician-rated
Yale-Brown Obsessive-Compulsive Scale Modified for
BDD. Secondary outcomes included measures of insight,
depression, quality of life, and global functioning. BDD
symptoms decreased significantly from pre- to posttreat-
ment and remained stable over the 12-month follow-up. At
this time point, 50% of participants were classified as
responders and 23% as remitters. Participants remained
significantly improved on all secondary outcomes at
12-month follow-up. Neither baseline insight nor baseline
depression predicted long-term outcomes. The positive
effects of CBT appear to be durable up to 12-month
follow-up. However, the majority of patients remained
symptomatic and vulnerable to a range of risks at 12-month
follow-up, indicating that longer-term monitoring is advis-
able in this population. Future research should focus on
enhancing the efficacy of CBT in order to improve
long-term outcomes.
Keywords: body dysmorphic disorder; children; adolescents;
cognitive-behavioral therapy
BODY DYSMORPHIC DISORDER (BDD) is characterized
by an excessive preoccupation with perceived
defects in appearance, causing significant distress
and/or impairment in functioning (American Psy-
chiatric Association, 2013). The disorder is rela-
tively common, with an estimated prevalence of
1.7–2.4% in community samples of adults (Koran,
Abujaoude, Large, & Serpe, 2008; Rief, Buhlmann,
Wilhelm, Borkenhagen, & Brähler, 2006; Veale,
Gledhill, Christodoulou, & Hodsoll, 2016). BDD
typically has its onset during adolescence, where it
can have a devastating impact on emotional,
educational, and social functioning (Albertini &
Phillips, 1999; Phillips et al., 2006). Moreover,
adolescent-onset BDD is associated with the devel-
opment of more severe symptoms, greater lifetime
comorbidity, and higher rates of attempted suicide,
compared with adult-onset BDD (Bjornsson et al.,
2013). This highlights the urgent need for effective
treatments for BDD in youth.
In adult populations, six randomized controlled
trials (RCTs) have demonstrated cognitive-behavioral
therapy (CBT) to be efficacious in reducing BDD
severity compared with no treatment or wait-list
control conditions (Rabiei, Mulkens, Kalantari,
Molavi, & Bahrami, 2012; Rosen, Reiter, &Orosan,
1995; Veale et al., 1996; Wilhelm et al., 2014),
supportive therapy (Enander et al., 2016), and anxiety
management (Veale, Anson, et al., 2014). To date,
only one RCT has evaluated CBT for BDD in youth
(Mataix-Cols et al., 2015). Encouragingly, this study
found that developmentally tailored CBT was effica-
cious compared with a control condition. The
between-group effect size was 1.13, 95% CI [0.31,
1.96] at posttreatment and 0.85, 95%CI [0.02, 1.69]
at 2-month follow-up, favoring the CBT intervention,
which is broadly in line with the results of adult trials.
Furthermore, CBT was found to be associated with
significant improvements in depressive symptoms,
insight, quality of life, and global functioning.
Although it is well established that CBT for BDD
is associated with significant symptom relief in the
short term, longer-term outcomes are less clear. A
recent meta-analysis of CBT for BDD concluded
that gains are likely to be maintained for a least 2–4
months following treatment (Harrison, Fernández
de la Cruz, Enander, Radua, & Mataix-Cols,
2016). Existing RCTs in adults have included
follow-up periods ranging from 1 (Veale, Anson,
et al., 2014) to 6 months (Rabiei et al., 2012;
Wilhelm et al., 2014), and have shown preservation
of gains over this period. To our knowledge, only
two studies have examined longer-term outcomes
(McKay, 1999; Veale, Miles, & Anson, 2015).
McKay (1999) found that gains were maintained at
2-year follow-up among 10 patients who had
received behavior therapy with or without an
additional relapse prevention program. In a larger
study, Veale et al. (2015) examined outcomes
among 30 patients 1–4 years after completing
CBT. Overall, symptoms remained stable and the
relapse rate was relatively low (n = 4, 13.3%).
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However, it is of note that 12 patients (30.8%) were
on medication at the long-term follow-up and 10
(25.6%)had received further psychological treatment,
whichmay have contributed to the positive outcomes.
Even less is known about longer-term effects of
CBT for BDD in adolescents. Preliminary data from
a small case series (Krebs, Turner, Heyman, &
Mataix-Cols, 2012) and an open trial (Greenberg,
Mothi, &Wilhelm, 2016) suggest that gains can be
maintained for 6 months following treatment, but
these studies have included small samples with the
largest assessing only eight participants at 6-month
follow-up (Greenberg et al., 2016). There is a clear
need to evaluate durability of effects in the longer
term and in larger samples.
The present study is a follow-up of the only RCT
to date that has evaluated CBT for BDD in youth
(Mataix-Cols et al., 2015). The RCT included 30
adolescents with BDD who were randomized to
receive 14 sessions of CBT over 4 months or to a
control condition involving written psychoeduca-
tional materials and weekly telephone monitoring
for 4 months. The controlled phase of the RCT
finished after a 2-month follow-up. After this time
point, patients in the control condition were offered
CBT. All participants continued to be assessed in a
naturalistic design up to 12 months posttreatment.
The current study included all participants who
received CBT, regardless of the condition to which
they were initially allocated. Our primary aim was
to examine outcomes associated with CBT for BDD
across the complete sample up to 1 year posttreat-
ment. We hypothesized that CBT would be
associated with a significant improvement in BDD
symptoms and that treatment gains would be
maintained up to the 12-month follow-up. The
second aim was to explore the long-term effects of
CBT on a range of secondary outcomes. We
expected CBT to be associated with improvements
in depression, insight, quality of life, and global
functioning, and that participants would remain
improved with respect to these outcomes at
12-month follow-up. The third and final aim was
to explore possible predictors of long-term out-
come, namely insight and depressive symptoms.
While previous studies have not consistently found
that insight and depression are reliable predictors of
outcome in BDD (Harrison et al., 2016; Veale et al.,
2015), these potential predictors have not been
examined in adolescent samples.
Methods
participants
Thirty adolescents (26 female) aged 12–18 years
with a diagnosis of BDD participated in the original
RCT, 26 of whom commenced a course of CBT and
were included in the current study. Participants
were recruited through the National and Specialist
OCD (obsessive-compulsive disorder), BDD, and
Related Disorders Clinic for Young People at the
Maudsley Hospital, London. Eligibility criteria for
participants were as follows: (a) ages 12–18 years;
(b) a diagnosis of BDD made according to the
Diagnostic and Statistical Manual of Mental
Disorders, Fourth Edition (DSM-IV; American
Psychiatric Association, 2000); (c) stable psycho-
tropic medication for 12 weeks prior to randomi-
zation (if relevant); (d) no plans to commence or
increase the dose of psychotropic medication (if
relevant); (e) willingness to receive psychological
treatment; (f) willingness/ability to travel to the
clinic for CBT; and (g) a score of 24 or higher on the
Yale-Brown Obsessive-Compulsive Scale Modified
for BDD–Adolescent version (BDD-YBOCS-A;
Phillips et al., 1997).
Exclusion criteria were (a) current or past
diagnosis of schizophrenia or bipolar affective
disorder, current alcohol or substance dependence,
severe disabling neurological disorder, global intel-
lectual disability, autism spectrum disorder, or an
emerging borderline personality disorder requiring
treatment in its own right; (b) suicidal intent that
requires hospitalization; (c) English too poor to
engage in treatment; and (d) characteristics inter-
fering with completion of treatment (e.g., selective
mutism). Further information about the methods of
the original RCT can be found elsewhere
(Mataix-Cols et al., 2015).
design
The current study was a naturalistic long-term
follow-up of a sample recruited to a single-blind
RCT. In the original RCT, 15 participants were
randomized to receive CBT and 15 were randomized
to a control group (see Mataix-Cols et al., 2015 for
power calculation). The control group received
written materials containing age-appropriate infor-
mation about BDD (although not information per-
taining to treatment of BDD), and weekly telephone
calls to monitor mood and suicidal ideation. Six
months after randomization, the participants in the
control group were offered the opportunity to cross
over to receive CBT. Participants from both arms of
the original RCT were followed up 2, 6, and 12
months after completing CBT.
measures
BDD diagnosis was made according to DSM-IV
criteria (American Psychiatric Association, 2000)
using the BDD section of the Structured Clinical
Interview for DSM-IV (SCID-I; First, Spitzer,
Gibbon, & Williams, 2001). Comorbid psychiatric
464 kreb s et al .
diagnoses were established using the child version
of the Anxiety Disorders Interview Schedule (ADI-
S-IV-C; Silverman & Albano, 1996). Both instru-
ments were completed at baseline. The SCID-I BDD
section was additionally administered at all subse-
quent time points.
Primary Outcome Measure
The BDD-YBOCS-A (Phillips et al., 1997) is a
w i d e l y u s e d 1 2 - i t em s em i s t r u c t u r e d
clinician-administered interview that rates the
severity of BDD symptoms during the past week
(score range 0–48). Internal consistency in the
current study was good (Cronbach’a alpha = .79).
Secondary Outcome Measures
Brown Assessment of Beliefs Scale (BABS; Eisen et
a l . , 1998) . The BABS is a seven- i tem,
clinician-administered scale assessing the degree to
which body-image beliefs are delusional. Total
scores range from 0 to 24, with higher scores
reflecting greater delusionality. The BABS has
shown to be a reliable and valid measure of
insight/delusionality in patients with BDD (Phillips,
Hart, Menard, & Eisen, 2013). Cronbach’s alpha
for the current study was .82.
Appearance Anxiety Inventory (AAI; Veale,
Eshkevari, et al., 2014). The AAI is a 14-item
self-report measure of BDD-related cognitive and
behavioral processes. The AAI has been found to
have good test–retest reliability and convergent
validity in the measurement of appearance anxiety.
It is also sensitive to change during treatment
(Veale, Anson, et al., 2014). Excellent internal
consistency was demonstrated in the current study
(Cronbach’s alpha = .92).
Cosmetic Procedures Screening Questionnaire
(COPS; Veale et al., 2012). The COPS is a
nine-item, self-report measure of BDD symptoms
that generates a total score ranging from 0 to 72.
The COPS has demonstrated good internal consis-
tency, test–retest reliability, convergent validity,
and sensitivity to change (Veale et al., 2012).
Cronbach’s alpha for the current study was .88.
Body Image Quality of Life Inventory (BIQLI;
Cash & Fleming, 2002; Cash, Jakatdar, & Williams,
2004). The BIQLI is a 19-item, self-report measure
of quality of life associatedwith body image concerns.
Themeasure has showngood internal consistency and
unidimensionality in both sexes (Cash et al., 2004).
Cronbach’s alpha for the current study was .78.
Beck Depression Inventory for Youth (BDI-Y;
Beck, Beck, & Jolly, 2001). The BDI-Y is a 20-item
self-report measure of depressive symptoms, which
has good internal consistency and test-criterion
validity. Internal consistency in the current study
was excellent (Cronbach’s alpha = .91).
Children's Global Assessment Scale (CGAS;
Shaf fe r e t a l . , 1983) . The CGAS is a
clinician-rated measure of global functioning that
yields a single score ranging from 1 to 100. It has
been found to be reliable between raters and across
time and has demonstrated both discriminant and
concurrent validity (Shaffer et al., 1983).
Clinical Global Impression–Severity Scale (CGI-S;
Busner & Targum, 2007). The CGI-S is a
clinician-rated measure of overall severity of the
disorder. The CGI-S is a 7-point clinician-rated scale
that is widely used in mental health treatment trials.
procedure
All participants commenced a 14-session course of
manualized CBT for BDD. The core components of
the treatment were psychoeducation about BDD
(Sessions 1–2), exposure with response prevention
(ERP; Sessions 3–12), and relapseprevention (Sessions
13–14). Additional therapeutic techniques (e.g., mir-
ror retraining and attention training) were used when
needed, as guided by the individual formulation, to
promote engagement with ERP (see Mataix-Cols et
al., 2015 for further details of treatment). Parents/
carers were generally involved in psychoeducation
sessions and in the remainder of treatment to varying
degrees primarily depending on the developmental
level of the young person, the extent to which parents
were directly involved in accommodating BDD
symptoms, and the degree to which parental involve-
ment might inhibit disclosure/engagement with the
young person. Participants were offered 1-hour CBT
booster sessions 2, 6, and 12 months after completing
the course of CBT. Booster sessions involved review-
ing progress, setting future goals, and identifying
strategies for achieving these targets.
Outcomes were assessed via clinician-rated inter-
views and self-report questionnaires at pre- and
posttreatment and at 2-, 6- and 12-month follow-up.
The BDD-YBOCS-A and the AAI were also complet-
ed at midtreatment (Session 7). Measures were
administered by a trained independent assessor. In
addition to the standardized measures, assessors
systematically asked participants if there had been
any change in psychotropic medication or if they had
received further psychological treatment. They also
asked participants if they desired, had sought a
consultation for, and/or had undergone any cosmetic
procedure.
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statistical analysis
Mixed-effects regression analyses for repeated
measures with maximum likelihood estimation
(MLE) of parameters were implemented in Stata.
Mixed-effects models use all available data, can
properly account for correlation among repeated
measurements on the same subject, have greater
flexibility to model time effects, and can handle
missing data (Gueorguieva & Krystal, 2004). For
each outcome measure, the model included fixed
effects of time (baseline, midtreatment [available
only for the BDD-YBOCS-A and the AAI], post-
treatment, and 2-, 6-, and 12-month follow-up) and
subject effects as a random intercept factor to
account for the variances between participants and
within participants. Within-group effect sizes for
change across the baseline and the subsequent
follow-up time points were calculated with Cohen’s
d (Cohen, 1988). Additionally, percentages of
treatment responders and remitters were calculated
at each time point. Following previous BDD
research (Phillips, Hart, & Menard, 2014), treat-
ment response was defined as a reduction ≥30% in
the BDD-YBOCS-A score. Remission was defined
as loss of DSM-IV BDD diagnosis (as assessed by
the SCID-I). Linear regression was used to explore
Randomized (N=30)
Allocated to CBT (n=15)
- Received CBT (n=15)
- Did not receive CBT (n=0)
Allocated to Control Group (n=15)
- Received control intervention (n=14)
- Did not receive control intervention (n=1)
Able to cross-over to receive CBT (n=14)
- Accepted CBT (n=11)
- Did not receive CBT  (n=3)
o Declined (n=1)
o No longer met criteria for BDD (n=2)
Total who received CBT (n = 26)
- Completed CBT (n = 25)
- Dropped out (n = 1)
Followed-up at two months (n = 23)
Lost to follow-up (n = 2)
o Unreachable (n = 1)
o Refused (n =1)
Followed-up at six months (n = 22)
Lost to follow-up (n = 1)
o Refused (n = 1)
Followed-up at twelve months (n=22)
Lost to follow-up (n = 0)
12-month follow-up
Six-month follow-up
Two-month follow-up
CURRENT STUDY
CONTROLLED PHASE OF THE TRIAL
CBT Intervention
Stopped SSRI (n=1)
Started SSRI (n=1)
Started inpatient treatment (n=1)
Stopped SSRI (n=1)
Increased SSRI dose (n=1)
Started SSRI (n=1)
Stopped SSRI (n=1)
Increased SSRI dose (n=1)
Started psychotherapy (n=1)
Received risk management (n=1) 
Increased SSRI dose (n=1)
Started SSRI (n=1)
FIGURE 1 Flow diagram of study participants. Note. CBT = cognitive-behavioral therapy; SSRI = selective serotonin
reuptake inhibitor.
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whether level of insight and depressive symptoms
were predictors of long-term treatment response. In
this model, both baseline BABS and baseline BDI-Y
scores were entered as independent variables, along
with the initial BDD-YBOCS score in order to
control for baseline symptom severity. The
BDD-YBOCS score at 12-month follow-up was
the dependent variable. Alpha (two-tailed) was set
at p b 0.05 for all analyses.
Results
participants
Figure 1 shows the number of participants recruited
and followed up. Of the 15 participants initially
randomized to the control condition, one dropped
out immediately after randomization, two no
longer met diagnostic criteria for BDD after 6
months and did not cross over to receive CBT, and
one declined CBT. Therefore, a total of 11
participants from the control condition crossed
over to receive CBT. All participants initially
randomized to the CBT arm (n = 15) accepted
treatment, meaning that a total 26 adolescents
commenced CBT. Of those, 25 participants com-
pleted a course of CBT, 23 completed 2-month
follow-up assessments, and 22 completed 6- and
12-month follow-ups. There were no differences in
demographic or clinical characteristics between
those who were followed up to 12 months (n =
22) versus those who dropped out (n = 4).
In the final sample (n = 26), the majority of
participants were female (n = 22, 84.6%) with a
mean age of 16.2 (SD = 1.6) and a mean age of
onset of BDD of 12.5 (SD = 1.7). Most participants
were White (n = 22, 84.6%), and the most common
appearance concerns were facial features (n = 12,
46.2%), skin (n = 4, 15.4%), and hair (n = 3,
11.5%). Over half of the participants (n = 14,
53.8%) had delusional insight into their perceived
defect (defined as a total BABS score ≥18 and a
score of 4 on the first item, indicating complete
conviction in their belief; Phillips et al., 2012). Half
of the sample (n = 13, 50.0%) wanted surgery to
correct their perceived defects at baseline.
Ten participants (38.5%) had previously received
CBT for BDD and 10 (38.5%) had had a trial of
one or more selective serotonin reuptake inhibitor
(SSRI). Five participants (19.2%) continued to take
an SSRI when they started CBT. The majority (n =
16, 61.5%) were not attending school or attending
sporadically due to BDD. Twelve participants
(46.2%) had current or past self-harm, and four
(15.4%) had previously attempted suicide. Twenty
participants (76.9%) met diagnostic criteria for at
least one additional psychiatric disorder. The most
common comorbidities were mood disorders
(major depressive disorder or dysthymia; n = 10,
38.5%) and social phobia (n = 9, 34.6%).
primary outcome
Estimated mean BDD-YBOCS-A scores and stan-
dard errors (SEs) from the mixed-effects model for
each time point are shown in Table 1 (for raw
means and SDs, see Supplementary Table A1). The
linear mixed-effect regression model revealed that
there was a significant effect of time at all time
points, compared with baseline, indicating that
symptoms remained improved throughout
fol low-up (see Table 2 and Figure 2) .
Within-group effect sizes for the BDD-YBOCS-A
with respect to the baseline scores increased
nonsignificantly from 1.31 at posttreatment to
1.70 at 12-month follow-up (see Table 3).
Pairwise comparisons between the different time
points revealed that there was a significant decrease
in the BDD-YBOCS-A scores during the course of
Table 1
Model Estimates Across Time Points for Each Outcome Measure From the Linear Mixed-Effects Models
Measures Baseline Midtreatment
(Session 7)
Posttreatment
(Session 14)
2-month
follow-up
6-month
follow-up
12-month
follow-up
Mean SE Mean SE Mean SE Mean SE Mean SE Mean SE
BDD-YBOCS-A 36.96 1.97 31.2 1.99 25.70 2.02 26.50 2.04 24.12 2.10 22.23 2.07
AAI 38.20 2.75 32.4 2.75 22.33 2.84 23.41 2.91 24.37 2.99 25.30 3.14
BABS 18.71 1.23 – – 13.94 1.27 16.37 1.27 16.33 1.30 15.33 1.28
COPS 56.96 3.53 – – 39.67 3.73 40.93 3.84 40.87 3.95 41.04 4.02
BIQLI -30.95 3.67 – – -16.21 3.86 -21.05 4.00 -21.37 4.07 -21.80 4.34
BDI-Y 68.04 2.81 – – 57.56 2.96 60.70 3.00 62.19 3.08 61.45 3.19
CGAS 40.15 2.52 – – 50.60 2.66 51.05 2.63 53.72 2.66 57.13 2.69
CGI-S 4.77 0.25 – – 3.47 0.26 3.58 0.26 3.68 0.26 3.44 0.27
Note. BDD-YBOCS-A = Yale-Brown Obsessive-Compulsive Scale Modified for Body Dysmorphic Disorder–Adolescent version; AAI =
Appearance Anxiety Inventory; BABS = Brown Assessment of Beliefs Scale; COPS = Cosmetic Procedures Screening Questionnaire;
BIQLI = Body Image Quality of Life Inventory; BDI-Y = Beck Depression Inventory–Youth; CGAS = Children's Global Assessment Scale;
CGI-S = Clinical Global Impression–Severity.
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the active treatment (from pretreatment to mid-
treatment: estimated mean difference = –5.70, 95%
CI [–9.46, –1.94], SE = 1.92, p = .003), and from
midtreatment to posttreatment (estimated mean
difference = –5.57, 95% CI [–9.40, –1.73], SE =
1.95, p = .004), but no further significant change
thereafter (all p N .05), indicating that the BDD
symptoms remained stable during the follow-up.
Nine out of 26 participants (34.6%) were classified
as responders at posttreatment. This number in-
creased to 10 (38.5%) at 2- and 6-month follow-up,
and to 13 (50.0%) at 12-month follow-up. Five
participants (19.2%) were classified as remitters at
posttreatment and at 2-month follow-up, and six
participants (23.1%) at 6- and 12-month follow-up.
secondary outcomes
Table 1 shows the estimated means and SE for all of
the secondary outcome measures at each time point
(raw means and SD are shown in Supplementary
Table A1). The results of the linear mixed-effect
regression models for the secondary outcomes are
shown in Table 2. The results demonstrate signif-
icant improvements across all measures at each time
point, relative to baseline. Within-group effect sizes
across time points for all secondary outcome
measures are shown in Table 3.
insight and depressive symptoms as
predictors of treatment response
Results of a linear regression model indicated that
neither baseline BABS nor baseline BDI-Y scores
significantly predicted treatment response at
12-month follow-up (baseline BABS: β = .094, SE =
.654,p= .730; baselineBDI-Y:β= .303,SE= .285,p=
.241).
protocol deviations
A number of participants changed, obtained, or
stopped treatment off protocol (see Figure 1). One
participant commenced fluoxetine (40 mg) before
Session 7 and then started additional CBT for BDD as
an inpatient after posttreatment, following a suicide
attempt. Two other participants commenced medica-
tion: one between posttreatment and 2-month
follow-up (40 mg fluoxetine), and one between 6-
and 12-month follow-up (100 mg sertraline). An
additional three participants increased medication:
one between posttreatment and 2-month follow-up
(from 20 to 30 mg fluoxetine), one between 2- and
6-month follow-up (from 50 to 100 mg sertraline),
and one between 6- and 12-month follow-up (from
100 to 150 mg sertraline). Three participants discon-
tinued SSRI medication: one during active treatment,
one between posttreatment and 2-month follow-up,Ta
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and one between 2- and 6-month follow-up. One
further patient commenced psychotherapy for depres-
sion between 2- and 6-month follow-up and one
received ongoing risk management after 2-month
follow-up following a suicide attempt. Analyses were
repeated excluding all data points after treatment
changes for these participants; results remained largely
unchanged (see Supplementary Tables A2 and A3).
adverse events
Two participants attempted suicide during the
study. In one case, the attempt occurred during
the controlled phase of the trial as previously
reported (Mataix-Cols et al., 2015). The other case
attempted suicide on two separate occasions
between the 2- and the 6-month follow-ups. On
both occasions, the patient took an overdose of
FIGURE 2 Time effects on the primary outcome measure (BBD-YBOCS-A), derived from
the mixed-effects regression model. Error bars indicate 95% confidence intervals. Note.
BDD-YBOCS-A = Yale-Brown Obsessive-Compulsive Scale Modified for BDD–Adolescent
version; 2m FU = 2-month follow-up; 6m FU = 6-month follow-up; 12m FU = 12-month
follow-up.
Table 3
Within-Group Cohen’s d Effect Sizes From Baseline to Each Follow-Up Time Point
Measures Within-group Cohen’s d (95% CI)
Baseline to midtreatment
(Session 7) outcomes
Baseline to posttreatment
(Session 14) outcomes
Baseline to 2-month
follow-up outcomes
Baseline to 6-month
follow-up outcomes
Baseline to 12-month
follow-up outcomes
BDD-YBOCS-A 0.86 (0.28 to 1.43) 1.31 (0.69 to 1.92) 1.27 (0.65 to 1.89) 1.50 (0.84 to 2.15) 1.70 (1.03 to 2.36)
AAI 0.44 (-0.11 to 1.00) 1.25 (0.61 to 1.87) 1.12 (0.48 to 1.75) 1.19 (0.52 to 1.84) 1.22 (0.51 to 1.91)
BABS – 0.85 (0.26 to 1.44) 0.45 (-0.12 to 1.02) 0.42 (-0.17 to 1.01) 0.54 (-0.04 to 1.12)
COPS – 1.05 (0.43 to 1.67) 0.94 (0.31 to 1.57) 1.18 (0.50 to 1.84) 0.99 (0.32 to 1.64)
BIQLI – -0.80 (-1.42 to -0.17) -0.59 (-1.22 to 0.04) -0.59 (-1.23 to 0.05) -0.61 (-1.28 to 0.07)
BDI-Y – 0.75 (0.15 to 1.35) 0.54 (-0.06 to 1.14) 0.54 (-0.08 to 1.15) 0.67 (0.02 to 1.31)
CGAS – -1.00 (-1.60 to -0.39) -1.10 (-1.69 to -0.49) -1.15 (-1.75 to -0.53) -1.38 (-2.01 to -0.73)
CGI-S – 1.22 (0.60 to 1.83) 1.01 (0.41 to 1.61) 0.98 (0.37 to 1.57) 1.13 (0.50 to 1.74)
Note. BDD-YBOCS-A = Yale-Brown Obsessive-Compulsive Scale Modified for Body Dysmorphic Disorder–Adolescent version; AAI =
Appearance Anxiety Inventory; BABS = Brown Assessment of Beliefs Scale; COPS = Cosmetic Procedures Screening Questionnaire;
BIQLI = Body Image Quality of Life Inventory; BDI-Y = Beck Depression Inventory–Youth; CGAS = Children's Global Assessment Scale;
CGI-S = Clinical Global Impression–Severity.
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medication, the first of which required emergency
treatment in the hospital. The participant remained
in the trial and completed a 12-month follow-up
assessment, but also received ongoing risk manage-
ment from the local Child and Adolescent Mental
Health Service.
other significant events
Of the 22 patients who completed a 12-month
follow-up assessment, six (27%) continued to want
cosmetic treatment (compared with 13 [50%] at
baseline), five (23%) of whom had sought consul-
tations for one or more procedure during follow-up
(rhinoplasty, n = 2; breast augmentation, n = 2;
blepharoplasty, n = 1; liposuction, n = 1; lip fillers, n
= 1; Botox, n = 1). Of these five participants, none
had achieved a full remission from BDD and only
one was classified as a treatment responder at
12-month follow-up. There was no difference in
baseline BABS scores between those who did and
did not want surgery at 12-month follow-up (M =
20.9 andM = 18.9, respectively; t = –1.04, p = .31),
nor was there any difference in baseline BDI-Y
scores (M = 73.57 andM = 67.06, respectively; t = –
1.72, p = .10). By 12-month follow-up, no
participants had undergone cosmetic procedures
or had concrete plans in place to do so.
Three participants (13.6% of female participants;
ages 14, 17, and 18 years) reported unplanned
pregnancies—one during the course of CBT and
two during follow-up. In two cases, pregnancies
resulted from one-off sexual encounters that took
place under the influence of alcohol, and the
pregnancies were perceived negatively by the
patients and were terminated. In the third case,
the patient was in a long-term relationship and the
pregnancy was perceived positively.
Discussion
To our knowledge, the current study represents the
largest evaluation of CBT for adolescents with BDD
to date. Moreover, this is the first study to examine
longer-term outcomes in youth. In line with our
primary hypothesis, CBT was found to be associ-
ated with a significant reduction in BDD symptoms
and gains were maintained through to 12-month
follow-up. Within-group effect sizes were large and
increased nonsignificantly from 1.31 at posttreat-
ment to 1.70 at 12-month follow-up. Participants
received a total of three booster CBT sessions over
the 12-month follow-up and therefore maintenance
of gains was achieved with a low level of therapist
input. Although a number of patients (n = 6, 23%)
received further treatment for BDD off protocol
during the follow-up period, this does not account
for our findings as the results remained largely
unchanged after excluding these patients from the
analyses. Regarding individual outcomes, the num-
ber of patients classified as treatment responders
increased from 35% at posttreatment to 50% at
12-month follow-up, indicating that some patients
made further gains during follow-up, perhaps as
they continued to utilize CBT strategies.
With respect to our second hypothesis, improve-
ments were observed on all secondary outcome
measures (including depressive symptoms, insight,
quality of life, and global functioning) at 12-month
follow-up, relative to baseline, suggesting that CBT
for BDD is associated with long-term benefits
across a number of domains. In relation to the
final aim, neither baseline levels of insight nor
depressive symptoms predicted BDD symptom
severity at 12-month follow-up. Although this is
inconsistent with the clinical suggestion that BDD
patients with poor insight and depression are
difficult to treat, it is nevertheless in line with the
recent meta-analytic finding that these factors do
not predict CBT response (Harrison et al., 2016).
Further research in larger samples is needed to
identify significant predictors and moderators of
CBT response, as this could inform clinical decision
making and the development of more effective
interventions.
The improvements associated with CBT reported
here are comparable to those seen in previous RCTs
(Enander et al., 2016; Mataix-Cols et al., 2015;
Rabiei et al., 2012; Rosen et al., 1995; Veale,
Anson, et al., 2014; Veale et al., 1996; Wilhelm et
al., 2014). Our finding that gains are maintained
for a year following treatment extends previous
findings in adolescents that have shown, in small
samples, that gains can be preserved for up to 6
months (Greenberg et al., 2016). Our results are in
line with the adult literature demonstrating main-
tenance of gains for up to 4 years (Veale et al.,
2015). The results of the current study must be
interpreted cautiously due to the lack of control
condition, but they suggest that developmentally
tailored CBT is an effective treatment for adolescent
BDD in the longer term, supporting the National
Institute for Health and Clinical Excellence (2005)
guidelines.
Although our findings are encouraging, it must
be noted that by 12-month follow-up only half of
the sample could be classified as treatment
responders. Furthermore, two participants (8%)
attempted suicide, consistent with previous re-
search demonstrating high rates of suicidality
among adolescents with BDD (Bjornsson et al.,
2013). In addition, while there was a marked
reduction in the number of adolescents wanting
cosmetic treatments for their perceived appearance
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defects relative to baseline, nevertheless five pa-
tients sought consultations for cosmetic procedures
by 12-month follow-up (all of whom still met
diagnostic criteria for BDD). This is concerning
given that cosmetic treatment is frequently associ-
ated with negative outcomes in BDD (Bowyer,
Krebs, Mataix-Cols, Veale, &Monzani, 2016). It is
possible that BDD patients are at particular risk of
seeking cosmetic surgery after failing to respond to
CBT, as failure of a psychological approach may
strengthen their view that physically changing their
appearance is the only solution to their difficulties.
Also of note, three participants reported unplanned
pregnancies during follow-up. In two instances, the
pregnancies resulted from one-off sexual encoun-
ters while under the influence of alcohol. The
clinical impression was that these patients were
vulnerable to such encounters due to their strong
desire for social acceptance, low self-esteem, and
social naïvety, all of which were directly related to
their BDD. Future research should examine possi-
ble methods for enhancing outcomes in youth with
BDD, such as delivering more CBT sessions (Veale,
Anson, et al., 2014; Wilhelm et al., 2014) and/or
combining CBT with pharmacotherapy as recom-
mended by clinical guidelines (National Institute for
Health and Clinical Excellence, 2005).
The results of this study should be considered
within the context of a number of limitations. First,
this represents a naturalistic follow-up of an RCT.
The absence of a control group means that we
cannot conclude that long-term improvements in
BDD symptoms and secondary outcomes were an
effect of CBT. Second, the sample size was too small
to enable us to examine a comprehensive set of
potential moderators of treatment response (e.g.,
comorbidities, age of BDD onset, chronicity).
Third, the study included a relatively severe sample
of adolescents with BDD (mean baseline
BDD-YBOCS-A of 37). The majority of patients
were highly functionally impaired (e.g., unable to
attend school full-time) and almost half had been
nonresponsive to previous attempts at CBT or
pharmacotherapy. It is possible that superior results
would be obtained in a less severe sample. Fourth,
despite best efforts, there were a number of protocol
deviations, with 11 patients changing or obtaining
treatment off protocol. Fifth, outcomes were
assessed by a single rater only, meaning that we
were unable to demonstrate interrater reliability.
In summary, the current study suggests that
developmentally tailored CBT is associated with
significant improvements in BDD symptoms among
adolescents, and that gains are maintained for the
year following completion of treatment with
minimal therapist input. The long-term effects of
CBT for adolescent BDD require further evaluation
using even longer follow-up periods. Future studies
should seek to identify predictors and moderators
of long-term outcome in an effort to understand
barriers to recovery. Our findings suggest that a
significant proportion of adolescents who receive
CBT for BDD continue to experience clinically
significant symptoms in the longer term, and
remain vulnerable to a range of potential risks
and negative outcomes (e.g., cosmetic surgery,
suicidal behavior, risky sexual behaviors). For this
reason, we recommend long-term monitoring of
these patients. Efforts must be focused on better
understanding the etiological and maintenance
factors associated with this disorder in order to
improve upon existing CBT interventions, and
enhance long-term prognosis.
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